Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Lorenzo Rossi, Chiara Biagioni, Amelia McCartney, Ilenia Migliaccio, Giuseppe Curigliano, Giuseppina Sanna, Erica Moretti, Alessandro M Minisini, Saverio Cinieri, Carlo Tondini, Grazia Arpino, Antonio Bernardo, Angelo Martignetti, Emanuela Risi, Marta Pestrin, Luca Boni, Matteo Benelli, Laura Biganzoli, Angelo Di Leo, Luca Malorni

Research output: Contribution to journalArticlepeer-review

Abstract

Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes time-to-treatment failure beyond progression on palbociclib or palbociclib+endocrine therapy in patients enrolled in the phase II, multicenter TREnd trial. Our results indicate that there is limited benefit from post-palbociclib treatment, regardless of the type of therapy received. A small population of long responders were identified who demonstrated ongoing benefit from a subsequent line of endocrine therapy after progression to palbociclib-based regimens. A translational research program is ongoing on this population of outliers.

Original languageEnglish
Pages (from-to)71
JournalBreast cancer research : BCR
Volume21
Issue number1
DOIs
Publication statusPublished - May 29 2019

Fingerprint Dive into the research topics of 'Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial'. Together they form a unique fingerprint.

Cite this